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Abstract
Listed in this section are hydrolases not accumulated in other parts of the Concise Guide, such as
monoacylglycerol lipase and acetylcholinesterase. Pancreatic lipase is the predominant mechanism of fat
digestion in the alimentary system; its inhibition is associated with decreased fat absorption. CES1 is present at
lower levels in the gut than CES2 (P23141), but predominates in the liver, where it is responsible for the
hydrolysis of many aliphatic, aromatic and steroid esters. Hormone-sensitive lipase is also a relatively non-
selective esterase associated with steroid ester hydrolysis and triglyceride metabolism, particularly in adipose
tissue. Endothelial lipase is secreted from endothelial cells and regulates circulating cholesterol in high density
lipoproteins.
Contents
This is a citation summary for Hydrolases in the Guide to Pharmacology database (GtoPdb). It exists purely as
an adjunct to the database to facilitate the recognition of citations to and from the database by citation
analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here
under database links.
GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a
reference work which is most usefully represented as an on-line database. As in any publication this work
should be appropriately cited, and the papers it cites should also be recognized. This document provides a
citation for the relevant parts of the database, and also provides a reference list for the research cited by those
parts.
Please note that the database version for the citations given in GtoPdb are to the most recent preceding version
in which the family or its subfamilies and targets were substantially changed. The links below are to the current
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            AChE(acetylcholinesterase (Cartwright blood group))
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465
            BChE(butyrylcholinesterase)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2471
            DAGLα(Diacylglycerol lipase α)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1396
            DAGLβ(Diacylglycerol lipase β)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1397
            CES1(carboxylesterase 1)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2592
            NTPDase-1(ectonucleoside triphosphate diphosphohydrolase 1)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2888
            NTPDase-2(ectonucleoside triphosphate diphosphohydrolase 2)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2889
            epoxide hydrolase 2
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2970
            FAAH(Fatty acid amide hydrolase)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1400
            Leukotriene A4 hydrolase
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1395
            LIPE(lipase E, hormone sensitive type)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2593
            LIPG(lipase G, endothelial type)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2591
            MAGL(Monoacylglycerol lipase)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1399
            nudix hydrolase 7
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3085
            O-GlcNAcase
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3101
            PNLIP(pancreatic lipase)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2590
            PLA2-G7
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1432
            sPLA2-2A
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1417
            PLD2
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1434
            vanin 1
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3063
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